ECM
TBPH icon

ExodusPoint Capital Management’s Theravance Biopharma TBPH Stock Holding History

ExodusPoint Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-28,437
Closed -$254K – 1961
2025
Q1 		$254K Buy
+28,437
New +$265K ﹤0.01% 1263
2024
Q4 		– Sell
-38,018
Closed -$306K – 2047
2024
Q3 		$306K Sell
38,018
-42,937
-53% -$372K ﹤0.01% 1354
2024
Q2 		$686K Buy
80,955
+200
+0.2% +$1.8K ﹤0.01% 1136
2024
Q1 		$724K Buy
+80,755
New +$748K 0.01% 1046
2023
Q4 		– Sell
-117,318
Closed -$1.01M – 2035
2023
Q3 		$1.01M Buy
117,318
+13,637
+13% +$132K 0.01% 966
2023
Q2 		$1.07M Buy
+103,681
New +$1.14M 0.01% 1075
2022
Q2 		– Sell
-53,850
Closed -$515K – 2435
2022
Q1 		$515K Buy
+53,850
New +$528K 0.01% 1489
2021
Q4 		– Sell
-14,791
Closed -$109K – 2580
2021
Q3 		$109K Sell
14,791
-76,073
-84% -$851K ﹤0.01% 1895
2021
Q2 		$1.32M Buy
+90,864
New +$1.71M 0.01% 858
2020
Q4 		– Sell
-18,472
Closed -$273K – 2364
2020
Q3 		$273K Sell
18,472
-12,933
-41% -$242K 0.01% 1326
2020
Q2 		$659K Buy
+31,405
New +$807K 0.02% 943

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ExodusPoint Capital Management's TBPH Position: Q2 2025 in Review

ExodusPoint Capital Management sold out of Theravance Biopharma (TBPH) in Q2 2025, closing a stake of 28,437 shares — an estimated $254K sold.

ExodusPoint Capital Management first reported a position in TBPH in Q2 2020 and held it in 11 quarters. The position peaked at $1.32M in Q2 2021. 135 funds tracked by Wall St. Rank hold TBPH as of Q2 2025.

  • ExodusPoint Capital Management reported no remaining Theravance Biopharma position as of Q2 2025 after selling out during the quarter.
  • ExodusPoint Capital Management sold 28,437 Theravance Biopharma shares in Q2 2025, an estimated $254K.
  • ExodusPoint Capital Management first reported a position in Theravance Biopharma in Q2 2020 and held it in 11 quarters.
  • ExodusPoint Capital Management's Theravance Biopharma position peaked at $1.32M in Q2 2021.
  • 135 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2025.

Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.